Curebase, a San Francisco, CA-based provider of decentralized clinical research software and services, raised $15M in Series A funding.
The round, which brings the total raised to $19M, was led by GGV Capital with participation from Xfund, Bold Capital, and several other institutional funds. In conjunction with the funding, Jeff Richards, managing partner, GGV Capital, will join Curebase’s board of directors.
The company intends to use the funds for platform development, expansion of its market presence and consolidation of the technology.
Led by Tom Lemberg, founder and CEO, Curebase is a provider of decentralized clinical research software and services, with the goal of powering research where any patient, anywhere can be part of clinical trials at home and with their own doctor. The platform enables any patient and any healthcare provider to be part of a clinical study, accelerating enrollment and enabling novel study designs with diverse populations. The company operates as a complete eClinical software platform and virtual research site with features including digital recruitment, ePRO, eCOA, telemedicine, eConsent, eSource, and more.
Curebase is currently operating over a dozen clinical studies that are each at the forefront of decentralized research methodologies. These methodologies reach patients wherever they live and are powered by software applications for patients, physicians, and sponsors. The company’s other study designs leverage real-world physicians to supply ultrasounds, colonoscopy records, and other data categories. Curebase also played a significant role in innovating drug study designs, including a study in which its platform virtualized all the visit types to have mobile phlebotomists collect ECG, vitals, and blood draws, while the patient’s clinician was able to use the platform to conduct telemedicine visits and remotely view patient data.